BUSINESSMARKETWATCH
GSK just announced its biggest purchase in eight years to rev up cancer portfolio it had previously wound down
GSK, a U.K. pharmaceutical company, announced a $10.6 billion acquisition of Nuvalent, a U.S.-listed biotech firm, marking its largest purchase in eight years to strengthen its cancer portfolio.
Related Signal
Adjacent reporting
- GSK to buy US cancer treatment firm Nuvalent for $10.6bn
- STAT+: GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B
- GSK to buy US cancer treatment firm Nuvalent for $10.6bn
- GSK in talks to buy cancer biotech Nuvalent for more than $9bn
- Chiesi Agrees to Buy KalVista Pharmaceuticals for $1.9 Billion
- Johnson & Johnson is buying cancer drug biotech Firefly Bio for $1 billion